Advertisement
Screener

DERMATA THERAPEUTICS, INC. (DRMA) Debt Conversion, Converted Instrument, Amount

2.8 / 5 stars · 68/120 Roast Me

DERMATA THERAPEUTICS, INC. Debt Conversion, Converted Instrument, Amount

DERMATA THERAPEUTICS, INC. (DRMA) reported Debt Conversion, Converted Instrument, Amount of $2.30 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-21.

Discontinued › Cash Flow › Financing Activities

us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-02-21

  • DERMATA THERAPEUTICS, INC. debt conversion, converted instrument, amount for the quarter ending 2022-03-31 was $2.30M.
  • DERMATA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2022 was $2.30M, a 0.00% change from fiscal 2021.
  • DERMATA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2021 was $2.30M, a 100.87% increase from fiscal 2020.
  • DERMATA THERAPEUTICS, INC. debt conversion, converted instrument, amount for fiscal 2020 was $1.15M.
Period endDebt Conversion, Converted Instrument, Amount 1 monthDebt Conversion, Converted Instrument, Amount 3 monthDebt Conversion, Converted Instrument, Amount 12 month
2022-12-31$2.30M
10-K · filed 2023-02-21
2022-03-31$2.30M
10-Q · filed 2022-05-16
2021-12-31$2.30M
10-K · filed 2022-03-28
2020-12-31$1.15M
10-K · filed 2023-02-21
2020-10-31$1.15M
10-Q · filed 2022-11-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15